Bliss GVS Pharma Q2 Results FY27: PAT Jumps 86.57% to Rs 53.34 Cr, Revenue Rs 313.37 Cr
- October 29, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Bliss GVS Pharma Q2 Results FY27 were declared on 29 October 2026 on a Consolidated basis. Revenue rose 28.22% to Rs 313.37 Cr from Rs 244.40 Cr a year earlier, while net profit grew 86.57% to Rs 53.34 Cr from Rs 28.59 Cr. These quarterly results also show Operating Profit up 85.33% to Rs 80.58 Cr, so YoY growth is strong across all three lines.
Bliss GVS Pharma Ltd (BLISSGVS) Q2 Results FY27 announced on 29 October 2026, covering the company’s financial performance for the July to September quarter. The results date brought consolidated results with revenue of Rs 313.37 Cr and PAT of Rs 53.34 Cr, and Bliss GVS Pharma Q2 Results FY27 show revenue 28.22% higher than the same quarter last year on a Consolidated basis.
Bliss GVS Pharma Q2 Results are examined here through a results analysis that covers the financial highlights, business drivers, outlook and risks. The figures below set out how revenue, Operating Profit and net profit moved against the same quarter last year, starting with the Financial Highlights table.
Click Here – Get Free Investment Predictions
Bliss GVS Pharma Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 313.37 Cr | Rs 244.4 Cr | +28.22% YoY |
| Operating Profit | Rs 80.58 Cr | Rs 43.48 Cr | +85.33% YoY |
| Net Profit (PAT) | Rs 53.34 Cr | Rs 28.59 Cr | +86.57% YoY |
Source: company filing for Bliss GVS Pharma Q2 Results FY27, 29 October 2026. Figures in Rs Crore, Consolidated basis.
Key Takeaways from Bliss GVS Pharma Q2 Results: What Stands Out
- Revenue of Rs 313.37 Cr: sales grew 28.22% from Rs 244.40 Cr in the same quarter last year, a strong YoY growth figure.
- Net profit of Rs 53.34 Cr: PAT rose 86.57% from Rs 28.59 Cr, so net profit grew much faster than revenue.
- Operating Profit of Rs 80.58 Cr: this line increased 85.33% from Rs 43.48 Cr, close to the pace of net profit in Bliss GVS Pharma Q2 Results FY27.
- Net profit margin of 17.0%: the margin improved from 11.7% in the comparison quarter, as the supplied figures show.
- Next step: the performance analysis below compares all three lines and notes what to track in later disclosures.
Bliss GVS Pharma Q2 Results FY27: Performance Analysis
Bliss GVS Pharma Q2 Results FY27 show a quarter in which revenue, Operating Profit and net profit all moved sharply higher against the same quarter last year. Revenue reached Rs 313.37 Cr against Rs 244.40 Cr, a rise of 28.22%. Operating Profit rose to Rs 80.58 Cr, and net profit rose to Rs 53.34 Cr.
The results analysis shows YoY growth of 85.33% in Operating Profit, from Rs 43.48 Cr to Rs 80.58 Cr, alongside 86.57% growth in net profit from Rs 28.59 Cr to Rs 53.34 Cr. The supplied data confirms the movement but does not establish the specific cause, and Univest readers can compare all three lines across quarters.
For Bliss GVS Pharma Q2 Results, both profit lines grew by more than three times the 28.22% revenue growth rate. The quarterly results therefore leave investors watching whether revenue, Operating Profit and net profit keep moving together in the next filing, which is where the discussion turns to the business factors.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – The results analysis points to three business factors, and the first is the top line. Revenue grew 28.2% year on year to Rs 313.37 Cr in the latest quarter, and this growth frames the Bliss GVS Pharma Q2 Results FY27 numbers.
Net Profit and Margin – Net profit rose 86.6% year on year to Rs 53.34 Cr, and net profit margin improved to 17.0% from 11.7% in the comparison quarter. This is the bottom line of the quarterly results moving ahead of revenue.
Return on Capital Employed – Return on capital employed was 17.40% in FY26. This is a full-year measure that sits alongside the quarter, and it leads directly into the outlook.
FY27 Outlook After Bliss GVS Pharma Q2 Results
The FY27 outlook after Bliss GVS Pharma Q2 Results depends on how the coming quarters build on this quarter. The results analysis records Operating Profit of Rs 80.58 Cr and net profit of Rs 53.34 Cr in Q2, and full-year FY27 results will depend on the quarters still to be reported.
Bliss GVS Pharma Q2 Results FY27 give investors a fixed reference for the next filing. The next disclosure will show how net profit moves from Rs 53.34 Cr and how revenue moves from Rs 313.37 Cr, and each new declaration can be followed on the Univest Screener, which brings the discussion to the risks.
Key Risks to Watch After Bliss GVS Pharma Q2 Results FY27
Volatile Quarterly Net Profit
Quarterly net profit has been volatile, ranging from Rs 23.27 Cr to Rs 53.34 Cr over the last 5 quarters. Bliss GVS Pharma Q2 Results FY27 sits at the top of that range, so YoY growth should be read with the wider quarterly pattern in mind.
Return on Equity Below 15%
Return on equity of 12.11% in FY26 is below 15%. This full-year ratio gives context to the quarterly profit growth, and it is a measure to monitor as later quarters are reported.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
In summary, Bliss GVS Pharma Q2 Results FY27 show revenue of Rs 313.37 Cr, Operating Profit of Rs 80.58 Cr and net profit of Rs 53.34 Cr in the quarterly results declared on 29 October 2026. The consolidated results record strong YoY growth, and readers following Bliss GVS Pharma Q2 Results should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Bliss GVS Pharma Q2 Results FY27
What are Bliss GVS Pharma Q2 Results FY27?
Ans. Bliss GVS Pharma Q2 Results FY27 are the Consolidated quarterly results for July to September 2026, with revenue of Rs 313.37 Cr and net profit of Rs 53.34 Cr. These figures appear in the Quick Answer and Financial Highlights.
What is the results date for Bliss GVS Pharma Q2 Results FY27?
Ans. Bliss GVS Pharma declared its results on 29 October 2026 for the July to September quarter. Alongside this, the results date marks the filing behind every figure here, as the introduction notes.
What revenue was reported in Bliss GVS Pharma Q2 Results FY27?
Ans. Bliss GVS Pharma Q2 Results FY27 report revenue of Rs 313.37 Cr, compared with Rs 244.40 Cr a year earlier. This means revenue rose 28.22%, as shown in the Financial Highlights table and Performance Analysis.
What net profit was reported in Bliss GVS Pharma Q2 Results FY27?
Ans. Net profit in Bliss GVS Pharma Q2 Results FY27 was Rs 53.34 Cr, compared with Rs 28.59 Cr a year earlier. This means PAT rose 86.57%, which the Key Takeaways section lists right after the revenue move.
How much YoY growth did revenue show in Bliss GVS Pharma Q2 Results FY27?
Ans. Revenue showed YoY growth of 28.22% in Bliss GVS Pharma Q2 Results FY27, moving from Rs 244.40 Cr to Rs 313.37 Cr. This sits alongside an 85.33% rise in Operating Profit, discussed in Performance Analysis.
Did net profit rise or fall in Bliss GVS Pharma Q2 Results?
Ans. Bliss GVS Pharma Q2 Results show net profit rising to Rs 53.34 Cr from Rs 28.59 Cr, a gain of 86.57%. So net profit grew faster than revenue, as the Performance Analysis section explains in more detail.
What was the Operating Profit in Bliss GVS Pharma Q2 Results FY27?
Ans. Operating Profit in Bliss GVS Pharma Q2 Results FY27 was Rs 80.58 Cr, up 85.33% from Rs 43.48 Cr a year earlier. This is the second fastest growth rate of the three lines, as listed in Key Takeaways.
Are Bliss GVS Pharma Q2 Results consolidated results or standalone results?
Ans. Bliss GVS Pharma Q2 Results are consolidated results, covering Bliss GVS Pharma Ltd on a Consolidated basis for the July to September 2026 quarter. This is why every figure in the article refers to consolidated results.
What business factors shaped Bliss GVS Pharma Q2 Results FY27?
Ans. The business factors listed for Bliss GVS Pharma Q2 Results FY27 are 28.2% revenue growth, 86.6% net profit growth, a 17.0% net profit margin and a 17.40% return on capital employed in FY26. Each is covered in Key Business Factors.
What are the key risks after Bliss GVS Pharma Q2 Results FY27?
Ans. The key risks after Bliss GVS Pharma Q2 Results FY27 are volatile quarterly net profit and a return on equity of 12.11% in FY26, which is below 15%. These are set out in the Key Risks section, alongside YoY growth.
What is the outlook after Bliss GVS Pharma Q2 Results?
Ans. The outlook after Bliss GVS Pharma Q2 Results rests on the coming quarters, with FY27 full-year results depending on later filings. This follows the Outlook section, which uses Q2 net profit of Rs 53.34 Cr as its reference point.
Where can I find the complete Bliss GVS Pharma Q2 Results FY27 data?
Ans. The complete Bliss GVS Pharma Q2 Results FY27 data sits in the Financial Highlights table of this article, which sets revenue, Operating Profit and net profit against the same quarter last year. Univest also keeps the company’s stock page.
